Onyx Pharmaceuticals (ONXX) – Bull of the Day
Source: http://www.zacks.com/commentary/9857/Onyx+Pharmaceuticals+%28ONXX%29+-+Bull+of+the+DayPosted on Monday, January 26th, 2009 | In Stocks to Watch
Onyx Pharmaceuticals, Inc. (ONXX) is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborator Bayer Healthcare, the company develops the small molecule drug Nexavar (sorafenib).
Nexavar sales in the third qurater of 2008 remained strong. This is mainly attributed to the market penetration in the liver cancer market, while Nexavar market share in kidney cancer market has stabilized due to heavy competition from Pfizer and Wyeth.
We expect continued Nexavar sales growth in 4Q08 and over the next several years since the label has expanded to liver cancer. In addition to the U.S. and E.U., Nexavar has been approved in South Korea and China for liver cancer. Nexavar has the potential to become a blockbuster. We maintain our Buy rating on Onyx shares with a price target of $45 per shares.
“ONXX” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Bayer, cancer, Cancer Therapies, China, Day Onyx Pharmaceuticals Inc.;, kidney cancer, Liver Cancer, molecule drug;, Nexavar, Onyx Pharmaceuticals;, Pfizer, south korea, Stocks to Watch, United States, USD, Wyeth, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.